Xerostomia Therapeutics Market Growth Insights: Revenue Predictions, Leading Companies, and Regional Analysis by 2032

𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐭𝐚𝐭𝐬:

• The xerostomia therapeutics market was valued at USD 2.08 billion in 2022.
• The market is anticipated to grow to USD 2.94 billion by 2032.
• It is anticipated to register a CAGR of 3.5% from 2023 to 2032.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐞𝐟𝐢𝐧𝐢𝐭𝐢𝐨𝐧:

Xerostomia, or dry mouth, is a condition where the salivary glands in the mouth don't make enough saliva to keep the mouth wet. It usually develops in patients who undergo head and neck radiation therapy for cancer treatment. Xerostomia can be treated with a variety of methods. Healthcare professionals may recommend over-the-counter products in the form of sprays, gels, and chewing gum. Other treatment options for the condition include the use of pilocarpine or systemic cholinergic drugs.

𝐂𝐥𝐢𝐜𝐤 𝐭𝐨 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐧𝐝 𝐃𝐫𝐢𝐯𝐞 𝐈𝐦𝐩𝐚𝐜𝐭𝐟𝐮𝐥 𝐃𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬: https://www.polarismarketresearch.com/industry-analysis/xerostomia-therapeutics-market/request-for-sample

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬:

• The rising prevalence of oral health conditions is one of the major factors propelling the xerostomia market demand. This is because xerostomia is a common side effect of various medications and treatments and contributes to the widespread occurrence of oral health conditions.
• The growing use of chemotherapy and radiotherapy to treat cancer is another factor contributing to increased demand for xerostomia therapeutics. While chemotherapy and radiotherapy are essential components of cancer therapy, they can have side effects, such as damage to salivary glands.

𝐓𝐨𝐩 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐧𝐭𝐬:

The key market participants adopt a multi-faceted strategy encompassing product portfolio development and distribution agreements. This approach enables them to maintain their market position and cater to the needs of patients and healthcare professionals. The xerostomia therapeutics market key players are:
• Acacia Pharma
• Colgate-Palmolive Company
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Lupin Pharmaceuticals Inc.
• OraCoat
• Parnell Pharmaceuticals, Inc.
• Pendopharm
• Pfizer Inc.
• Sun Pharmaceuticals Industries Ltd.

𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐍𝐨𝐰 𝐟𝐨𝐫 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: https://www.polarismarketresearch.com/industry-analysis/xerostomia-therapeutics-market/inquire-before-buying

𝐊𝐞𝐲 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

• The xerostomia therapeutics market was valued at USD 2.08 billion in 2022 and is projected to grow to USD 2.94 billion by 2032.
• The rising adoption of chemotherapy and radiotherapy in cancer treatment is one of the major factors driving the demand for xerostomia therapeutics.
• The market is primarily segmented based on type, product, and region.
• The key regions covered in the report are North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:

• The market is primarily segmented based on type, product, and region.
• By type analysis, the OTC segment accounted for the largest market share in 2022. The segment's dominance is primarily attributed to the extensive variety and widespread availability of OTC products.
• By product analysis, the salivary stimulants segment held a significant market share in 2022. This is primarily because salivary stimulants are essential for enhancing saliva production.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞: https://www.polarismarketresearch.com/industry-analysis/xerostomia-therapeutics-market

𝐗𝐞𝐫𝐨𝐬𝐭𝐨𝐦𝐢𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬

• The OTC segment dominated the market, as they are easily available, affordable, and have a higher efficacy rate
• The dentifrices segment will grow rapidly, as they are more efficient as they focus on improving the salivary stimulants by restoring essential salivary components, Calcium, and phosphate
• North America held the largest share, primarily due to patient awareness regarding the ill effects of xerostomia, effective treatment options via its well-developed medical infrastructure.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐏𝐌𝐑'𝐬 𝐗𝐞𝐫𝐨𝐬𝐭𝐨𝐦𝐢𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐂𝐨𝐯𝐞𝐫𝐚𝐠𝐞 𝐟𝐫𝐨𝐦 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐏𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬:
https://www.whatech.com/og/markets-research/medical/852050-xerostomia-therapeutics-market-to-booming-anticipated-grow-at-3-5-cagr-revenue-to-cross-2-94-billion-by-2032-glaxosmithkline-plc-hikma-pharmaceuticals-plc.html

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

Epilepsy Drugs Market: https://www.polarismarketresearch.com/industry-analysis/global-epilepsy-drugs-market

Vitamin K2 Market: https://www.polarismarketresearch.com/industry-analysis/vitamin-k2-market

Covid-19 Diagnostics Market: https://www.polarismarketresearch.com/industry-analysis/covid-19-diagnostics-market

Oxygen Scavengers Market: https://www.polarismarketresearch.com/industry-analysis/oxygen-scavenger-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.